Jaguar Health Subsidiary to Provide Crofelemer to Infant in EU for Compassionate Use
MT Newswires • Jul 22, 2026
Read articleAdditional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID)
ACCESS Newswire • Jul 22, 2026
Read articlePresentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF)
ACCESS Newswire • Jun 30, 2026
Read articleLife Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
GlobeNewswire • Jun 26, 2026
Read articleJaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend
ACCESS Newswire • Jun 25, 2026
Read articleJaguar Health Files New Animal Drug Application For Full FDA Approval Of Canine Diarrhea Therapy
MT Newswires • Jun 23, 2026
Read article